HELSINKI—Bone Index, a pioneering medical technology company headquartered in Finland, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was led by Shanghai-based Lynx Financial, a fund with a dedicated focus on healthcare and life sciences, and was supported by contributions from existing investors.
The funds raised will be directed towards scaling up the company’s manufacturing capabilities and enhancing market promotion strategies, in response to escalating demand for bone diagnostic products in the North American and Asia-Pacific regions. This move aligns with Bone Index’s strategic expansion plans and the growing need for advanced bone health diagnostics globally.
In tandem with the investment, Bone Index has forged a partnership with Lynx Financial to introduce its innovative technologies and products in the targeted regions. This collaboration is set to leverage Lynx Financial’s market expertise and resources to broaden the reach of Bone Index’s novel diagnostic solutions.
At the heart of Bone Index’s innovation is the Bindex system, a breakthrough diagnostic tool for osteoporosis that delivers rapid and precise results. Utilizing proprietary algorithms, Bindex estimates hip bone density by measuring the cortical bone thickness in the tibia, demonstrating up to 90% consistency with the dual energy X-ray absorptiometry (DXA) standard in various clinical trials.
The Bindex system is designed as a compact, handheld device, offering adaptability for early screening as well as in-hospital use. Its portability and accuracy are anticipated to alleviate the medical burden associated with traditional bone density assessments, making it a promising addition to the osteoporosis diagnostic landscape.- Flcube.com
